Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

NCT03788291 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia (CLL)
Small Lymphocytic Lymphoma (SLL)

Interventions

DRUG: Acalabrutinib
DRUG: Rituximab

Sponsor

University of Rochester